Endoscopy 2008; 40(12): 994-999
DOI: 10.1055/s-2008-1077785
Total Barrett Eradication review section

© Georg Thieme Verlag KG Stuttgart · New York

Total endoscopic eradication of Barrett's esophagus: Study methodology, candidate selection, and clinical outcomes

N.  J.  Shaheen1 , S.  J.  Spechler2
  • 1University of North Carolina, Chapel Hill, North Carolina USA
  • 2VA North Texas Healthcare System, and the University of Texas Southwestern Medical Center, Dallas, Texas, USA
Further Information

Publication History

Publication Date:
08 December 2008 (online)

Introduction

This issue of Endoscopy focuses on total endoscopic eradication of Barrett's esophagus, a condition described by the Australian surgeon Norman Rupert Barrett in 1950 [1] . This paper considers methodological aspects of studies of ablative therapies for Barrett's esophagus, and how the choices made by investigators with respect to study methodology and candidate selection might impact the clinical outcomes observed in these studies.

References

  • 1 Barrett N R. Chronic peptic ulcer of the oesophagus and “oesophagitis”.  Br J Surg. 1950;  38 175-182
  • 2 McClave S A, Boyce jr. H W, Gottfried M R. Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion.  Gastrointest Endosc. 1987;  33 413-416
  • 3 Choi D W, Oh S N, Baek S J. et al . Endoscopically observed lower esophageal capillary patterns.  Korean J Intern Med. 2002;  17 245-248
  • 4 Vianna A, Hayes P C, Moscoso G. et al . Normal venous circulation of the gastroesophageal junction. A route to understanding varices.  Gastroenterology. 1987;  93 876-889
  • 5 Paull A, Trier J S, Dalton M D. et al . The histologic spectrum of Barrett's esophagus.  N Engl J Med. 1976;  295 476-480
  • 6 Spechler S J, Goyal R K. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett.  Gastroenterology. 1996;  110 614-621
  • 7 Chandrasoma P. Pathophysiology of Barrett's esophagus.  Semin Thorac Cardiovasc Surg. 1997;  9 270-278
  • 8 Dresner S M, Griffin S M, Wayman J. et al . Human model of duodenogastro-oesophageal reflux in the development of Barrett's metaplasia.  Br J Surg. 2003;  90 1120-1128
  • 9 Takubo K, Aida J, Naomoto Y. et al . Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma.  Hum Pathol. 2008; 
  • 10 Playford R J. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus.  Gut. 2006;  55 442
  • 11 Shaheen N J, Crosby M A, Bozymski E M, Sandler R S. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?.  Gastroenterology. 2000;  119 333-338
  • 12 Wang K K, Sampliner R E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.  Am J Gastroenterol. 2008;  103 788-797
  • 13 Eisen G M, Montgomery E A, Azumi N. et al . Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials.  Gastrointest Endosc. 1999;  50 814-818
  • 14 Sharma P, Falk G W, Weston A P. et al . Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.  Clin Gastroenterol Hepatol. 2006;  4 566-572
  • 15 Konda V J, Ross A S, Ferguson M K. et al . Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?.  Clin Gastroenterol Hepatol. 2008;  6 159-164
  • 16 Montgomery E, Bronner M P, Goldblum J R. et al . Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.  Hum Pathol. 2001;  32 368-378
  • 17 Alikhan M, Rex D, Khan A. et al . Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice.  Gastrointest Endosc. 1999;  50 23-26
  • 18 Overholt B F, Lightdale C J, Wang K K. et al . Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.  Gastrointest Endosc. 2005;  62 488-498
  • 19 Shaheen N J, Sharma P, Overholt B F. et al . A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett's esophagus (BE) containing dysplasia: interim results of the AIM Dysplasia Trial.  Gastroenterology. 2008;  134 A37
  • 20 Schoenfeld P, Cook D, Hamilton F. et al . An evidence-based approach to gastroenterology therapy. Evidence-Based Gastroenterology Steering Group.  Gastroenterology. 1998;  114 1318-1325
  • 21 Spechler S J. Dysplasia in Barrett's esophagus: limitations of current management strategies.  Am J Gastroenterol. 2005;  100 927-935
  • 22 Ormsby A H, Petras R E, Henricks W H. et al . Observer variation in the diagnosis of superficial oesophageal adenocarcinoma.  Gut. 2002;  51 671-676
  • 23 Skacel M, Petras R E, Gramlich T L. et al . The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.  Am J Gastroenterol. 2000;  95 3383-3387
  • 24 Attwood S E, Lewis C J, Caplin S. et al . Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus.  Clin Gastroenterol Hepatol. 2003;  1 258-263
  • 25 Gurski R R, Peters J H, Hagen J A. et al . Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.  J Am Coll Surg. 2003;  196 706-712
  • 26 Bright T, Watson D I, Tam W. et al . Randomized trial of argon plasma coagulation versus endoscopic surveillance for barrett esophagus after antireflux surgery: late results.  Ann Surg. 2007;  246 1016-1020
  • 27 Medical Dictionary for Regulatory Activities (MedDRA). http://www.meddramsso.com

N. J. ShaheenMD 

University of North Carolina School of Medicine
CB#7080

Chapel Hill, NC 27599-7080
USA

Fax: 01-919-843-2508

Email: nshaheen@med.unc.edu

    >